Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be between at least 18 years of age and less than 80 years of age.~* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving intracoronary abciximab and/or aspiration thrombectomy.~* He/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.~* Subject must have evidence of acute ST-segment elevation myocardial infarction with TIMI 0 or 1 flow, or visible thrombi (thrombus grade ≥ 3)~* Target lesion(s) must be located in a native coronary artery in the proximal to mid segment with estimated reference diameter of ≥ 2.5 mm and ≤ 4.0 mm.~* Target lesion(s) must be amenable for percutaneous coronary intervention.~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Abciximab, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)~* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.~* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.~* Baseline hemogram with Hb\<10g/dL or PLT count \<100,000/μL~* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.~* Patients with severe LV systolic dysfunction (LVEF\<25%) or in cardiogenic shock~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intracoronary abciximab (Type: ACTIVE_COMPARATOR): Intracoronary injection of bolus abciximab
- Aspiration thrombectomy (Type: ACTIVE_COMPARATOR): Aspiration thrombectomy
- Both use (Type: ACTIVE_COMPARATOR): Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).